 | Up a level |
Journal Article
Ghofrani, Hossein-Ardeschir, Grimminger, Friedrich 
ORCID: 0000-0001-8725-6276, Gruenig, Ekkehard, Huang, Yigao, Jansa, Pavel ORCID: 0000-0002-3711-7064, Jing, Zhi-Cheng ORCID: 0000-0003-0493-0929, Kilpatrick, David, Langleben, David, Rosenkranz, Stephan, Menezes, Flavia, Fritsch, Arno, Nikkho, Sylvia and Humbert, Marc ORCID: 0000-0003-0703-2892
(2016).
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Lancet Resp. Med., 4 (5).
S. 361 - 372.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2213-2600
Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk Thomas, Cabrera, Roniel, Mueller, Udo, Menezes, Flavia, Ishida, Tatiane, Galle, Peter R. and El-Khoueiry, Anthony B. (2021). Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755